NYU Technologies In The News
BrainScope Company, Inc. announced the market release of its flagship Ahead 300 product, and will initiate a limited launch to a select group of thought leadersthrough its Centers of Excellence program later in the first quarter. These institutions will represent a cross-section of market segments including Urgent Care Clinics, Concussion Clinics, Emergency Medicine Departments, and University and Professional Sports. BrainScope will also be selling the Ahead 300 to various branches of the U.S. military and government. BrainScope’s technology is based on intellectual property and research from NYU based on the work of Dr. Leslie Prichep, Professor of Psychiatry at NYU School of Medicine.
Orca Pharmaceuticals, a developer of therapeutics for inflammation, has entered into a partnership agreement with AstraZeneca to develop novel agents against RORgamma, the master regulator for inflammatory Th17 cells. Orca was founded in 2013 and is based on research and intellectual property from Dr. Dan Littman, the Helen L. and Martin S. Kimmel Professor of Molecular Immunology and Howard Hughes Medical Institute (HHMI) Investigator.
BeneVir Biopharm, Inc, a developer of cancer immunotherapies, announced it closed a Series A investment by Pansend, LLC, an indirect wholly owned subsidiary of HC2 Holdings, Inc. BeneVir Biopharm was founded on NYU intellectual property and research by Dr. Ian Mohr, Professor of Microbiology at the NYU School of Medicine. Dr. Mohr’s research is focused harnessing oncolytic viruses as therapeutics for several types of cancers.
Soligenix, a clinical stage company, has acquired the rights for SGX301, a Phase 3 asset being developed for cutaneous T-cell lymphoma, from Hy Biopharma. Hy Biopharma was founded on NYU intellectual property and research from Drs. Daniel Meruelo, Professor of Pathology, and Dr. Gad Lavie.
Twitter has acquired Madbits, a startup founded on work by Dr. Yann LeCun, Silver Professor of Computer Science at NYU’s Courant Institute of Mathematical Sciences.
Janssen Biotherapeutics showcases collaboration with NYU at Annual BIO Convention
At the 2016 Annual BIO Convention in Philadelphia, Janssen Biotherapeutics presented an ongoing collaboration with NYU focused on developing novel therapeutics for Staphylococcus aureus. In addition to the presentation, a video was screened interviewing Dr. Victor Torres, Associate Professor of Microbiology and the NYU Principal Investigator on the project: